NCT00871741TerminatedPhase 2
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- GlaxoSmithKline
- Enrollment
- 16
- Locations
- 8
- Primary Endpoint
- Anti-PRP Antibody Concentrations ≥ 0.15 mg/mL
Study Overview
Brief Summary
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine given as a three-dose vaccination course at 3, 5 and 11 months of age.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 8 Weeks to 16 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •A male or female infant between, and including, 8 and 16 weeks at the time of the first vaccination.
- •Born after a gestation period of 36 to 42 weeks inclusive.
- •Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol.
- •Written informed consent obtained from the parent or guardian of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria
- •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •Administration of a vaccine not foreseen by the study protocol within 30 days prior to randomisation, or planned administration from randomisation to study Visit 3, or from 30 days before to 30 days after study Visit 4, with the exception of influenza and human rotavirus vaccines. The administration of other vaccines, including conjugated pneumococcal vaccine, is allowed during the period from one day after study Visit 3 to 31 days before study Visit
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
- •Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib and/or MenC vaccination or disease, including HBV vaccination at birth.
- •History of seizures or progressive neurological disease.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
- •Major congenital defects or serious chronic illness.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •Current febrile illness or axillary temperature >= 38.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration
Arms & Interventions
GSK2202083A GROUP
Experimental
Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
Intervention: GSK2202083A vaccine (Biological)
INFANRIX + MENJUGATE GROUP
Active Comparator
Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
Intervention: Menjugate (Biological)
INFANRIX + MENJUGATE GROUP
Active Comparator
Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
Intervention: Infanrix hexa (Biological)
Outcomes
Primary Outcomes
Anti-PRP Antibody Concentrations ≥ 0.15 mg/mL
Time Frame: At Month 3
As the study was terminated, no blood samples were taken. Hence no immunogenicity analyses were done.
Secondary Outcomes
- Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms(During the 8-day (Days 0-7) post-vaccination period following each dose and across doses)
- Number of Subjects With Serious Adverse Events (SAEs)(During the entire study period (from Month 0 to Month 9))
- Number of Subjects With Unsolicited Adverse Events AE(s)(During the 31-day (Days 0-30) post-vaccination period)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(During the 8-day (Days 0-7) post-vaccination period following each dose and across doses)
Investigators
Study Sites (8)
Loading locations...
Similar Trials
Completed
Phase 2
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsHaemophilus Influenzae Type bPoliomyelitisNeisseria MeningitidisAcellular PertussisDiphtheriaHepatitis BTetanusNCT01090453GlaxoSmithKline480
Completed
Phase 2
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniTetanusPoliomyelitisHaemophilus Influenzae Type bAcellular PertussisHepatitis BDiphtheriaNCT00970307GlaxoSmithKline421
Completed
Phase 2
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DosePoliomyelitisDiphtheriaAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniTetanusHaemophilus Influenzae Type bHepatitis BNCT01171989GlaxoSmithKline391
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenInfluenzaNCT01196988GlaxoSmithKline3,027
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female SubjectsInfections, PapillomavirusNCT00996125GlaxoSmithKline750